featured
-
New Insights Into Why Huntingtonās Disease Has Delayed Onset
A highly-anticipated scientific paper has landed! This new work challenges current theories in Huntingtonās disease research, uncovering how runaway CAG repeats erode cell identity in certain types of brain cells, leading to their death.
-
Spotting HD Early: The Clues Hidden in Young Brains
Researchers have detected early changes in brain scans and biomarkers in young people with the Huntingtonās disease gene, 20 years before symptoms are predicted to appear. These findings could help develop medicines to treat HD earlier in life.
-
Replacing What Is Lost: Regrowing Damaged Brain Cells for Huntingtonās Disease
Cell replacement therapy is making massive strides for other diseases. But what about Huntingtonās disease? Can we use technological advancements in this area to replace lost brain cells with the hope of repairing and reversing disease?
-
Decoding apathy in Huntingtonās disease: a new lens on motivation and decision-making
Apathy in Huntingtonās disease isnāt just a lack of motivationāitās a shift in how the brain weighs decisions. A new study sheds light on how targeted treatments could help restore motivation and improve quality of life.
-
2024: Year in Review
As we begin 2025, we look back on all of the Huntingtonās disease research news and progress the field has made in the last 12 months.
-
2024 HDBuzz Prize: A NEAT new dance partner for Huntingtin
Weāre proud to announce AJ Keefe as our last HDBuzz Prize winner of 2024! Our cells are an intricate choreography between various molecular dancers. Knowing who moves well with whom, and how that changes with disease, could help advance drugs for HD.
By AJ Keefe -
Moving into the Fast Lane: uniQure and the FDA Are on the Same Track for Accelerated Approval
In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of drugs for Huntingtonās disease.
-
Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several genetic diseases, including #Huntingtonsdisease and #spinocerebellarataxia
-
Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals
A new Phase 1 clinical trial for the huntingtin-lowering drug ALN-HTT02 was initiated this week with the first dose given. Read on to learn details about the trial and how it compares to other ongoing huntingtin-lowering trials in the clinic.
-
Giving Thanks to the Huntington's Disease Family Community for Advancing Research
At this time of giving, we want to give thanks to you, the Huntingtonās disease (HD) community, for all you have done for HD research, bringing us closer to medicines which will one day slow or halt HD.